MedTrace Logo

Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan

NCT01412398 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 446

Last updated 2018-01-19

No results posted yet for this study

Summary

This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients in continuous ambulatory peritoneal dialysis (CAPD) who have received Fosrenol for hyperphosphatemia. The objective of this study is to assess safety and efficacy of using Fosrenol in clinical practice. This study is also all case investigation of which the enrollment period is one year, and all patients in CAPD who received Fosrenol for hyperphosphatemia will be recruited and followed one year.

Conditions

  • Hyperphosphatemia

Interventions

DRUG

Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet

Patients in CAPD who have received Fosrenol for hyperphosphatemia

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-07
Primary Completion
2014-04-08
Completion
2016-09-01

Countries

  • Japan

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01412398 on ClinicalTrials.gov